Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Fig. 4

Cytokines profiles and hepatocellular carcinoma (HCC) prognosis. a & b Hierarchical clustering analysis of 6 serum cytokines profiles. Hierarchical clustering classified HCCs into 2 groups (“cytokines-elevated” and “cytokines-non-elevated”) in a comprehensive and non-arbitrary manner in cohorts 2 (a; sorafenib-treated patients) and 1 (b; hepatic arterial infusion chemotherapy [HAIC]). c & d Cytokines-elevated patients showed better survival compared to cytokines-non-elevated patients in cohort 2 (c; sorafenib-treated patients) but not in cohort 1 (d; HAIC-treated patients)

Back to article page